In today's globalized healthcare market, navigating international medical device registration is one of the most persistent headaches manufacturers face. It's rarely a technical problem. It's a coordination problem, spread across regulators who don't share a playbook.
This isn't a deep dive into any single market. It's a practical comparison of where the major regulatory systems diverge, where manufacturers actually get stuck, and what a smarter cross-market strategy looks like in practice.
Understanding Regional Regulatory Authorities
The global regulatory landscape for medical devices isn't one system with local variations. It's several distinct systems that happen to be solving a similar problem. ANVISA, the FDA, and the EU's MDR each classify devices differently, document differently, and move at different speeds, and those differences shape market entry strategy from day one, not just at the finish line.
We won't unpack every classification rule here. For a full breakdown of how ANVISA, FDA, and MDR actually differ, and what that means in practice, see our companion article: Comparative Classification of ANVISA, FDA, and MDR: Key Differences Explained.
Documentation Is Where Most Delays Start
Ask any regulatory team where a submission stalled, and the answer is rarely the product itself. It's the paperwork behind it. Keeping documentation consistent and complete across markets is one of the biggest sources of delay we see, and it usually comes down to a handful of recurring requirements.
- Instructions for Use (IFUs) — market-specific language and formatting requirements
- GMP documentation — proof of manufacturing quality that satisfies each authority's audit standard
- Laboratory-developed test certification — where applicable, and often handled inconsistently
- SaMD documentation — software as a medical device, an area most frameworks are still catching up on
Brazil Adds a Layer of Its Own
Brazil's regulatory environment is centralized under ANVISA in Brasília, and it comes with its own set of specifics that manufacturers used to the FDA or MDR often don't see coming. RDC 751/2022 restructured how devices are classified and registered, and it isn't a simple mirror of international norms. Add to that a requirement for specific local representation and a level of technical documentation detail that goes well beyond a lot of other markets, and it's easy to see why Brazil trips up manufacturers who assume one dossier fits everywhere. It doesn't, and treating it like it does is one of the most common causes of avoidable delay we see.
The real challenge isn't getting one approval. It's coordinating approvals across markets that rarely agree with each other.
Quality Management Systems Rarely Line Up
Quality management requirements sound like they should be the easy part, but they vary more than most manufacturers expect. Acceptance of MDSAP, the Medical Device Single Audit Program, isn't uniform across regions. GMP requirements differ from one jurisdiction to the next, and audit and inspection processes don't follow a shared calendar or a shared checklist. A quality system built for one market's expectations can still fall short somewhere else, not because it's weak, but because it wasn't built with the other market's specific asks in mind.
A Smarter Way to Approach Multiple Markets
None of this means starting from scratch in every jurisdiction. A unified documentation strategy, one built to satisfy several regulatory bodies at once, can cut a huge amount of duplicated work. In practice, that means maintaining consistent technical files across markets, using identification software that keeps versions and submissions organized, and establishing clear UDI protocols from the start rather than retrofitting them later. It's less about doing more work and more about not doing the same work five separate times.
You Don't Have to Navigate This Alone
Even with a strong internal process, most manufacturers get further, faster, with outside support. That usually means working with regulatory consultants who know the local terrain, keeping a close eye on regulatory updates as they happen rather than after the fact, and showing up at sector events like Hospitalar and Medica, where a surprising amount of practical, unofficial guidance gets exchanged in hallway conversations rather than official channels.
Where the Landscape Is Headed
The regulatory environment isn't static, and a few trends are worth watching closely. Digital health and SaMD regulations are evolving fast, often faster than the products they're meant to govern. Harmonization efforts between markets are gaining real momentum, even if full alignment is still a long way off. And several authorities are actively building simplified pathways for genuinely innovative devices, which is good news if your product qualifies, and one more reason to track each market's rules rather than assume they're frozen in place.
Turning This Into a Strategy
Putting all of this together, a few moves tend to make the biggest difference. On the process side, building a comparative documentation matrix across target markets exposes overlaps you can consolidate, and a centralized regulatory management system keeps submissions from slipping through the cracks as they multiply. On timing, it helps to prioritize markets by potential and complexity rather than tackling them alphabetically, and to plan parallel submissions where requirements overlap closely, the EU and UK being a common example. On cost and risk, starting with a less complex market builds a track record you can point to later, and local partnerships shorten the learning curve considerably. And on submission itself, pre-submission meetings with regulators, a running log of regulator Q&A, and a checklist built from your own past approvals tend to save more time than any single template ever will.
This is exactly the coordination problem BIHS was built to solve. As the regulatory operating arm of the Brisa Advisors ecosystem, we run the Brazil Registration Hosting Service, the BRHS, which lets foreign manufacturers register with ANVISA while keeping full economic and strategic ownership of that registration.
We act as the legal holder in Brazil, handling traceability, post-market surveillance, UDI, and import support, and we coordinate GMP, INMETRO, and ANVISA certification alongside it. For manufacturers already juggling FDA and MDR requirements elsewhere, that's one less market you have to solve entirely on your own.
Registering in Brazil Alongside Other Markets?
Let's talk about how the BRHS model fits into your existing regulatory strategy, without duplicating work you've already done elsewhere.